Oncologist-Directed Solutions for Cancer Therapy & Drug Discovery™
Certis PDOX mouse models have proven to be more clinically relevant
- PDOX: Patient-Derived Orthotopic Xenografts
- We surgically implant a tiny slice of the human patient’s tumor into the corresponding, or orthotopic, location (pancreas, liver, lung, etc.) in immunodeficient mice.
- Mouse tumor growth and metastasis replicates the tumor behavior in the patient – in contrast to subcutaneous and tumor transplant models.
- The technique is employed to provide individualized precision therapy for patients as well as a unique drug discovery platform.
PDOX: A Patient’s Story
PDOX Pre-Clinical Services
PDOX Roundtable: It’s About People
CERTIS IN THE NEWS
CERTIS ONCOLOGY ANNOUNCES CLIA CERTIFICATION FOR HIGH-COMPLEXITY TESTING
The Company has designed Laboratory Developed Tests for its innovative PDOX mouse modeling techniques to determine the best treatment options for cancer patients.
SAN DIEGO, JULY 16, 2018. Certis Oncology Solutions, Inc., a new precision medicine company focused on individualized patient care, today announced that it has received its CLIA Certificate of Registration for High-Complexity Testing. Certis will utilize the certificate to implement Laboratory Developed Tests for its Patient-Derived Orthotopic Xenograft (PDOX) mouse models.
Translational Oncology for Drug Development
PDOX xenograft models are a superior offering for simulating clinical trials.
Eckardt M.D., Russell T.A., Murakami T., Singh A.S., Kiyuna T., Igarashi K., Kawaguchi K., Li Y., Crompton J., Dry S.M., Federman N., Chmielowski B., Shurrell E., Hoffman R.M., Eilber F.C. Clinical factors that affect the establishment of soft tissue sarcoma patient-derived orthotopic xenografts: A UCLA sarcoma program prospective clinical trial. JCO Precision Oncology, 2017.
PDOX is a proven technique that increases the precision of cancer therapies and individualizes treatment.
There is an urgent need to personalize chemotherapy treatments.
1.68 million new cancer cases and more than 600,000 cancer deaths are projected in the USA alone this year. Half will be treated with chemotherapy. Our patented technique marks a medical breakthrough for chemo patients. We are advancing the industry from “therapy by best guess” to ”therapy by precision science.”
PDOX stands for Patient Derived Orthotopic Xenografts. This means that we transplant tumors from patients into mice where – thanks to our science – the tumors grow and metastasize the same way as in the patient. By growing multiple, simultaneous mouse implants, we can rapidly determine precise, personalized treatment for the patient.
We are working to take this life-saving technology out of the research lab and offer it to as many cancer patients as is possible.